Felix Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felix Müller has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
C. Mund
Degussa-Goldschmidt AG, Essen, Germany
1 shared publication- Charlotte Kloft
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy Freie Universität Berlin Berlin Germany
1 shared publication Davide Bindellini
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstrasse 31 12169 Berlin, Germany
1 shared publicationGerd Mikus
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstrasse 31 12169 Berlin, Germany; Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 419 69120 Heidelberg, Germany
1 shared publication- Günter Schmid
Siemens Energy Global GmbH & Co. KG Erlangen Germany
1 shared publication - Heiko Kuhn
Center for Advanced Biotechnology and Department of Biomedical Engineering, Boston University, MA 02215, USA
1 shared publication
Latest Publications
- Open Access
- 31 March 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 209, 107085
Breaking barriers: The novel in vitro microdialysis system enables reproducing in vivo extraction efficiencies of linezolid
- 31 March 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 209, 107085
Open AccessBreaking barriers: The novel in vitro microdialysis system enables reproducing in vivo extraction efficiencies of linezolid
- Open Access
- 20 April 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (4) , 379
Influence of Carbamazepine Dihydrate on the Preparation of Amorphous Solid Dispersions by Hot Melt Extrusion
Amorphous solid dispersions (ASDs) are commonly used in the pharmaceutical industry to improve the dissolution and bioavailability of poorly water-soluble drugs. Hot melt extrusion (HME) has been employed to prepare ASD based products. However, due to the narrow processing window of HME, ASDs are normally obtained with high processing temperatures and mechanical stress. Interestingly, one-third of pharmaceutical compounds reportedly exist in hydrate forms. In this study, we selected carbamazepine (CBZ) dihydrate to investigate its solid-state changes during the dehydration process and the impact of the dehydration on the preparation of CBZ ASDs using a Leistritz micro-18 extruder. Various characterization techniques were used to study the dehydration kinetics of CBZ dihydrate under different conditions. We designed the extrusion runs and demonstrated that: 1) the dehydration of CBZ dihydrate resulted in a disordered state of the drug molecule; 2) the resulted higher energy state CBZ facilitated the drug solubilization and mixing with the polymer matrix during the HME process, which significantly decreased the required extrusion temperature from 140 to 60 °C for CBZ ASDs manufacturing compared to directly processing anhydrous crystalline CBZ. This work illustrated that the proper utilization of drug hydrates can significantly improve the processability of HME for preparing ASDs.
- 20 April 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (4) , 379
Open AccessInfluence of Carbamazepine Dihydrate on the Preparation of Amorphous Solid Dispersions by Hot Melt Extrusion
Amorphous solid dispersions (ASDs) are commonly used in the pharmaceutical industry to improve the dissolution and bioavailability of poorly water-soluble drugs. Hot melt extrusion (HME) has been employed to prepare ASD based products. However, due to the narrow processing window of HME, ASDs are normally obtained with high processing temperatures and mechanical stress. Interestingly, one-third of pharmaceutical compounds reportedly exist in hydrate forms. In this study, we selected carbamazepine (CBZ) dihydrate to investigate its solid-state changes during the dehydration process and the impact of the dehydration on the preparation of CBZ ASDs using a Leistritz micro-18 extruder. Various characterization techniques were used to study the dehydration kinetics of CBZ dihydrate under different conditions. We designed the extrusion runs and demonstrated that: 1) the dehydration of CBZ dihydrate resulted in a disordered state of the drug molecule; 2) the resulted higher energy state CBZ facilitated the drug solubilization and mixing with the polymer matrix during the HME process, which significantly decreased the required extrusion temperature from 140 to 60 °C for CBZ ASDs manufacturing compared to directly processing anhydrous crystalline CBZ. This work illustrated that the proper utilization of drug hydrates can significantly improve the processability of HME for preparing ASDs.
- 1 November 2004
- Published by Walter de Gruyter GmbH in Tenside Surfactants Detergents
- Vol. 41 (5) , 230-234
Mesoscale Computer Simulations on the Phase Behavior of the Non-Ionic Surfactant C12E5
Dissipative Particle Dynamics is a mesoscopic simulation method which allows to predict the self-assembly of amphiphilic polymers and surfactants. It was possible to reproduce the phase behavior of the non-ionic surfactant C12E5 in water. The three different phases L1, La and L2 could be characterized with Dissipative Particle Dynamics.
- 1 November 2004
- Published by Walter de Gruyter GmbH in Tenside Surfactants Detergents
- Vol. 41 (5) , 230-234
Mesoscale Computer Simulations on the Phase Behavior of the Non-Ionic Surfactant C12E5
Dissipative Particle Dynamics is a mesoscopic simulation method which allows to predict the self-assembly of amphiphilic polymers and surfactants. It was possible to reproduce the phase behavior of the non-ionic surfactant C12E5 in water. The three different phases L1, La and L2 could be characterized with Dissipative Particle Dynamics.